Skip to main content

Investors

Ulisse Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.

About Us

We are technology leaders in distribuited and connected diagnostics


Investors

The Ulysses Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.


31 December, 2020

Updates and announcements

Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection


Hyris CE-IVD marked test for COVID human diagnostic "bKIT Virus Finder COVID-19" is at the core of the signature Article "Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection", from the Department of Laboratory Medicine of the National Institute for The Study and Treatment of Cancer IRCCS "Fondazione G Pascale" (IRCCS Pascale), of Naples (Italy)

The easy access to a quick diagnosis of coronavirus disease 2019 (COVID-19) is a key point to improve the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to contain its spread. Up to now, laboratory real-time PCR is the standard of care, but requires a fully equipped laboratory and significant infrastructure. Consequently, new diagnostic tools are required.

Professor Leonardo Miscio and his colleagues evaluated the diagnostic accuracy of Hyris point-of-care rapid test "bKIT Virus Finder COVID-19", both by a retrospective and a prospective analysis.

Results obtained are entirely comparable to the standard laboratory-based real-time PCR methods for all the analyzed samples, with a much faster result and no need for an equipped facility.

This authoritative Article furtherly strengthens the Hyris System's relevance for human diagnostic, now empowered via the CE-IVD marked 'bKIT Virus Finder COVID-19', as it represents indeed a promising tool to improve the health surveillance and to increase the overall capacity of SARS-CoV-2 testing.

Hyris System confirms to be a key asset in the global fight against the last Coronavirus.

Read the full article HERE